IS-003

IS-003 is an investigational T-cell receptor engineered T-cell (TCR-T) therapy currently in preclinical development by ImmunoScape. The therapy is derived from ImmunoScape's proprietary Deep Immunomics platform, which utilizes high-throughput screening of T-cell receptors from cancer patients to identify rare, high-avidity TCRs. IS-003 involves the genetic modification of a patient's T cells to express these specific TCRs, enabling the immune system to recognize and target specific antigens on tumor cells. While the specific target antigen for IS-003 has not been publicly disclosed, the program is part of a broader effort to develop next-generation cell therapies for solid tumors.